Synthesis and antitumor evaluation of glycyrrhetinic acid‐dithiocarbamate hybrids
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.202400421 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Jiahong Su und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. Hauptthemen laut MEDLINE: Glycyrrhetinic Acid, Antineoplastic Agents, Thiocarbamates. Die Arbeit nennt 109 Literaturangaben. Gefördert von: Office of Science & Technology of Luzhou, National Natural Science Foundation of China.
Abstract (Originalsprache)
Glycyrrhetinic acid (GA) is a naturally occurring triterpene compound. The aim of this study was to employ the pharmacophore hybrid strategy to merge GA with various dithiocarbamates and obtain novel compounds with better antitumor activities. We present a two‐step synthetic protocol wherein the GA derivative underwent reaction with carbon disulfide and various secondary amines in a one‐pot manner under mild conditions, facilitating the preparation of a series of structurally novel GA‐dithiocarbamate derivatives. Bioassay screening revealed that the representative compound 3c demonstrated the capacity to reduce the mitochondrial membrane potential in Hep3B and Huh‐7 cells, induce nuclear apoptosis, inhibit invasion and migration, and prompt both early and late apoptosis. Furthermore, our research findings indicated that this apoptotic phenomenon may be associated with the expression of Bcl‐2, Bax, Bak, PARP, and cleaved‐PARP proteins. Utilizing network pharmacology for predicting core targets and signaling pathways of compound 3c for hepatocellular carcinoma (HCC) treatment involved employing molecular docking models to demonstrate high affinity between compound and target protein. In conjunction with Western blot analysis, compound 3c may impact HCC through the PI3K‐AKT‐mTOR pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China.
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, South Sichuan Institute of Translational Medicine, Luzhou, China.
Förderung
- Office of Science & Technology of Luzhou
- National Natural Science Foundation of China
Zitieren
APA
Su, J., Wang, X., Li, S., Wu, X., Li, M., Du, F., Deng, S., Shen, J., Zhao, Y., Xiao, Z., & Chen, Y. (2025). Synthesis and antitumor evaluation of glycyrrhetinic acid‐dithiocarbamate hybrids. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400421
Vancouver
Su J, Wang X, Li S, Wu X, Li M, Du F, et al. Synthesis and antitumor evaluation of glycyrrhetinic acid‐dithiocarbamate hybrids. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400421
BibTeX
@article{Su2025,
author = {Su, Jiahong and Wang, Xingyue and Li, Sha and Wu, Xu and Li, Mingxing and Du, Fukuan and Deng, Shuai and Shen, Jing and Zhao, Yueshui and Xiao, Zhangang and Chen, Yu},
title = {Synthesis and antitumor evaluation of glycyrrhetinic acid‐dithiocarbamate hybrids},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.202400421}
}
EUVIMED